Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10910943 | Lung Cancer | 2015 | 7 Pages |
Abstract
Antibodies against immune checkpoints including CTLA-4, PD-1 and PD-L1 are increasingly being used in lung cancer. They are associated with novel, immune related toxicities not previously encountered with established treatments for lung cancer including colitis, hepatitis, rashes, neuropathies and other rarer immune mediated toxicities. Although generally these are low grade, there is a potential to be life threatening if not managed promptly. Early recognition of toxicity and institution of management algorithms are key to ensuring patient safety. We review the common toxicities and provide recommendations on their management.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Matthew Howell, Rebecca Lee, Samantha Bowyer, Alberto Fusi, Paul Lorigan,